Full Spectroscopic Model and Trihybrid Experimental-Perturbative-Variational Line List for ZrO

Zirconium monoxide (ZrO) absorption lines define rare S-type stars and are currently being sought on exoplanets. Successful detection is dependent on an accurate and comprehensive line list, with existing data not ideal for many applications. Specifically, the Plez \etal{} line list is near-complete but has insufficient accuracy for high-resolution cross-correlation, while the Sorensen \& Bernath data has high accuracy but only considers a small number of spectral bands. This article presents a novel spectroscopic model, variational line list and trihybrid line list for the main \ZrO{} isotopologue, as well as isotopologue-extrapolated hybrid line lists for the \isoa{}, \isob{}, \isoc{}, \isod{}~and \isoe{} isotopologues. These were constructed using \DUO{} based on icMRCI-SD/CASSCF~\abinitio{} electronic data calculated using \MOLPRO{}, experimental energies obtained from a previous \Marvel{} data compilation and perturbative energies from Sorensen \& Bernath. The new \ZrO{} \EXOMOL{}-style trihybrid line list, \LLname{}, comprises \noenergies{} energies (\noMaenergies{} experimental) and \notransitions{} transitions up to 30,000~\cm{} (333~nm) between ten low-lying electronic states (\ZrOX{}, \ZrOaa{}, \ZrOA{}, \ZrObb{}, \ZrOB{}, \ZrOC{}, \ZrOdd{}, \ZrOee{}, \ZrOff{} and \ZrOF{}). The inclusion of experimental energy levels in \LLname{} means ZrO will be much easier to detect using high-resolution ground-based telescopes in the 12,500 -- 17,500~\cm{} (571 -- 800~nm) spectral region. The inclusion of variational energy levels means that the ZorrO line list has very high completeness and can accurately model molecular absorption cross-sections even at high temperatures. The \LLname{} data will hopefully facilitate the first detection of ZrO in the atmosphere of a hot Jupiter exoplanet, or alternatively more conclusively exclude its presence

Novel methods of management of trapped dormia baskets in the pancreatic and biliary ducts

no abstract available; lette

Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry

Currently, chronic obstructive pulmonary disease (COPD) represents the fourth cause of death worldwide with significant economic burden. Comorbidities increase in number and severity with age and are identified as important determinants that influence the prognosis. In this observational study, we retrospectively analyzed data collected from the RePoSI register. We aimed to investigate comorbidities and outcomes in a cohort of hospitalized elderly patients with the clinical diagnosis of COPD. Socio-demographic, clinical characteristics and laboratory findings were considered. The association between variables and in-hospital, 3-month and 1-year follow-up were analyzed. Among 4696 in-patients, 932 (19.8%) had a diagnosis of COPD. Patients with COPD had more hospitalization, a significant overt cognitive impairment, a clinically significant disability and more depression in comparison with non-COPD subjects. COPD patients took more drugs, both at admission, in-hospital stay, discharge and 3-month and 1-year follow-up. 14 comorbidities were more frequent in COPD patients. Cerebrovascular disease was an independent predictor of in-hospital mortality. At 3-month follow-up, male sex and hepatic cirrhosis were independently associated with mortality. ICS-LABA therapy was predictor of mortality at in-hospital, 3-month and 1-year follow-up. This analysis showed the severity of impact of COPD and its comorbidities in the real life of internal medicine and geriatric wards

Appropriateness of antiplatelet therapy for primary and secondary cardio- and cerebrovascular prevention in acutely hospitalized older people

Aims: Antiplatelet therapy is recommended for the secondary prevention of cardio- and cerebrovascular disease, but for primary prevention it is advised only in patients at very high risk. With this background, this study aims to assess the appropriateness of antiplatelet therapy in acutely hospitalized older people according to their risk profile. Methods: Data were obtained from the REPOSI register held in Italian and Spanish internal medicine and geriatric wards in 2012 and 2014. Hospitalized patients aged 6565 assessable at discharge were selected. Appropriateness of the antiplatelet therapy was evaluated according to their primary or secondary cardiovascular prevention profiles. Results: Of 2535 enrolled patients, 2199 were assessable at discharge. Overall 959 (43.6%, 95% CI 41.5\u201345.7) were prescribed an antiplatelet drug, aspirin being the most frequently chosen. Among patients prescribed for primary prevention, just over half were inappropriately prescribed (52.1%), being mainly overprescribed (155/209 patients, 74.2%). On the other hand, there was also a high rate of inappropriate underprescription in the context of secondary prevention (222/726 patients, 30.6%, 95% CI 27.3\u201334.0%). Conclusions: This study carried out in acutely hospitalized older people shows a high degree of inappropriate prescription among patients prescribed with antiplatelets for primary prevention, mainly due to overprescription. Further, a large proportion of patients who had had overt cardio- or cerebrovascular disease were underprescribed, in spite of the established benefits of antiplatelet drugs in the context of secondary prevention